Can a nanoparticle vaccine train the body to fight HIV?

NCT ID NCT07757802

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether experimental HIV vaccines can safely teach the immune system to recognize and fight the virus. Healthy adults without HIV will receive a protein nanoparticle vaccine, followed by a booster—either another protein nanoparticle or an mRNA vaccine. The goal is to see if these combinations trigger the kind of immune responses that could eventually lead to broadly neutralizing antibodies against HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Experimental HIV vaccines: CH505 protein nanoparticles (DV901-NP and DV902-NP) and CH505 mRNA vaccines, given with an adjuvant (ACU-026-001-1)
What this could lead to: If successful, this could point toward an effective HIV vaccine that teaches the immune system to make broadly neutralizing antibodies, potentially protecting people from HIV.
What could go wrong: This is an early Phase 1 trial with only 54 participants, so it primarily tests safety and immune responses, not real-world protection. The vaccines may not produce the desired antibodies or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

BIDMC VCRS Site# 32077

Boston, Massachusetts, 02215, United States
Bridge HIV CRS Site# 30305

San Francisco, California, 94102, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Site# 30007

Boston, Massachusetts, 02115, United States
Penn Prevention CRS Site# 30310

Philadelphia, Pennsylvania, 19104, United States
The Ponce de Leon Center CRS Site# 5802

Atlanta, Georgia, 30308, United States
University of Pittsburgh CRS Site# 1001

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Vaccines to Prevent HIV Infection CRS Site# 31467

Rochester, New York, 14642, United States
Vanderbilt Vaccine (VV) CRS Site# 30352

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.